Cargando…
Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy
Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible meta...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699488/ https://www.ncbi.nlm.nih.gov/pubmed/36432650 http://dx.doi.org/10.3390/pharmaceutics14112458 |
_version_ | 1784839086108835840 |
---|---|
author | Alves, Renata Carolina Perosa Fernandes, Richard Lira de Farias, Renan da Silva, Patricia Bento Santos Faria, Raquel Quijia, Christian Rafael Galvão Frem, Regina Célia Azevedo, Ricardo Bentes Chorilli, Marlus |
author_facet | Alves, Renata Carolina Perosa Fernandes, Richard Lira de Farias, Renan da Silva, Patricia Bento Santos Faria, Raquel Quijia, Christian Rafael Galvão Frem, Regina Célia Azevedo, Ricardo Bentes Chorilli, Marlus |
author_sort | Alves, Renata Carolina |
collection | PubMed |
description | Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible metal–organic Frameworks (bio-MOFs). These may be promising and attractive for drug incorporation and release. The present study aims to develop a drug carrier system RCA (bioMOF-100 submitted to the activation process) containing incorporated curcumin (CCM), whose material surface is coated with folic acid molecules (FA) to promote the targeting of drug carrier systems to the tumor region. They were synthesized and characterized using several characterization techniques. The materials were submitted to drug encapsulation tests, whose encapsulation efficiency was 32.80% for CCM@RCA-1D. Using the (1)H nuclear magnetic resonance (NMR) spectroscopy technique, it was possible to verify the appearance of signals referring to folic acid, suggesting success in the functionalization of these matrices. In vitro tests such as cell viability and type of cell death were evaluated in both series of compounds (CCM@RCA-1D, CCM@RCA-1D/FA) in breast tumor lines. The results revealed low toxicity of the materials and cell death by late apoptosis. Thus, these results indicate that the matrices studied can be promising carriers in the treatment of breast cancer. |
format | Online Article Text |
id | pubmed-9699488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96994882022-11-26 Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy Alves, Renata Carolina Perosa Fernandes, Richard Lira de Farias, Renan da Silva, Patricia Bento Santos Faria, Raquel Quijia, Christian Rafael Galvão Frem, Regina Célia Azevedo, Ricardo Bentes Chorilli, Marlus Pharmaceutics Article Breast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible metal–organic Frameworks (bio-MOFs). These may be promising and attractive for drug incorporation and release. The present study aims to develop a drug carrier system RCA (bioMOF-100 submitted to the activation process) containing incorporated curcumin (CCM), whose material surface is coated with folic acid molecules (FA) to promote the targeting of drug carrier systems to the tumor region. They were synthesized and characterized using several characterization techniques. The materials were submitted to drug encapsulation tests, whose encapsulation efficiency was 32.80% for CCM@RCA-1D. Using the (1)H nuclear magnetic resonance (NMR) spectroscopy technique, it was possible to verify the appearance of signals referring to folic acid, suggesting success in the functionalization of these matrices. In vitro tests such as cell viability and type of cell death were evaluated in both series of compounds (CCM@RCA-1D, CCM@RCA-1D/FA) in breast tumor lines. The results revealed low toxicity of the materials and cell death by late apoptosis. Thus, these results indicate that the matrices studied can be promising carriers in the treatment of breast cancer. MDPI 2022-11-15 /pmc/articles/PMC9699488/ /pubmed/36432650 http://dx.doi.org/10.3390/pharmaceutics14112458 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alves, Renata Carolina Perosa Fernandes, Richard Lira de Farias, Renan da Silva, Patricia Bento Santos Faria, Raquel Quijia, Christian Rafael Galvão Frem, Regina Célia Azevedo, Ricardo Bentes Chorilli, Marlus Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title | Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title_full | Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title_fullStr | Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title_full_unstemmed | Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title_short | Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy |
title_sort | fabrication of functional biomof-100 prototype as drug delivery system for breast cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9699488/ https://www.ncbi.nlm.nih.gov/pubmed/36432650 http://dx.doi.org/10.3390/pharmaceutics14112458 |
work_keys_str_mv | AT alvesrenatacarolina fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT perosafernandesrichard fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT liradefariasrenan fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT dasilvapatriciabento fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT santosfariaraquel fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT quijiachristianrafael fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT galvaofremreginacelia fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT azevedoricardobentes fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy AT chorillimarlus fabricationoffunctionalbiomof100prototypeasdrugdeliverysystemforbreastcancertherapy |